{"denoms":[{"counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"81"},{"groupId":"BG003","value":"95"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"285"}],"units":"Participants"}],"groups":[{"description":"Participants with DLBCL received Selinexor in different Schedules; Schedule 1: \\<= 12 milligram per square meter (mg/m\\^2) per orally (PO) alternating 3 times per week with twice weekly dosing (1 day between doses); Schedule 2: \\> 12 mg/m\\^2 PO 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly (1 day between doses) during Weeks 1 and 2; Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab intravenous (IV) once weekly for Weeks 1-4 during different cycles. Each cycle was of 28 days (Schedule 8: 21 days of cycle) or 10 scheduled selinexor doses.","id":"BG000","title":"Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with NHL received Selinexor in different Schedules; Schedule 1: \\<= 12 mg/m\\^2 PO alternating 3 times per week with twice weekly dosing (1 day between doses); Schedule 2: \\> 12 mg/m\\^2 PO 3 times weekly for week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs 1 day apart (Schedule 3); Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 days between doses) to evaluate vs twice weekly (Schedules 3, 4, 5, and 6); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly \\[1 Day between doses\\] during weeks 1 and 2; Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab IV once weekly for Weeks 1-4) during different cycles. Each cycle was of 28 days (Schedule 8: 21 days of cycle) or 10 scheduled selinexor doses.","id":"BG001","title":"Non-Hodgkin Lymphoma (NHL) Excluding DLBCL"},{"description":"Participants with MM received Selinexor in different Schedules; Schedule 1: \\<= 12 mg/m\\^2 PO alternating 3 times per week with twice weekly dosing (1 Day between doses); Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; 3 doses (36 mg/m\\^2 total) in the 1-week run-in period; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 6: \\>= 35 mg/m\\^2 PO twice weekly with dexamethasone (20 mg twice weekly) on Days of twice weekly Selinexor dosing; Schedule 11: Group A: 40 mg; Group B: 60 mg; Group C: 80 mg twice weekly (Weeks 1, 2, and 3) at 3 fixed dose levels during different cycles. Each cycle was of 28 days or 10 scheduled selinexor doses.","id":"BG002","title":"Multiple Myeloma (MM)"},{"description":"Participants with AML received Selinexor in different Schedules; Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly (1 day between doses); Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3), Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 Days between doses) to evaluate vs. twice weekly (Schedules 3, 4, 5, and 6); Schedule 8: \\>=40 mg/m\\^2 PO twice weekly (1 Day between doses) during Weeks 1 and 2; Schedule 10: \\>= 55 mg/m\\^2 PO twice weekly PO (Weeks 1 and 2) in participants with AML/18-Day treatment-free interval) during different cycles. Each cycle was of 28 days (for schedule 8: 21-day of cycle) or 10 scheduled selinexor doses.","id":"BG003","title":"Acute Myeloid Leukemia (AML)"},{"description":"Participants with other hematological malignancies (Acute lymphoblastic leukemia \\[ALL\\], Chronic myelogenous leukemia \\[CML\\] and chronic lymphocytic leukemia \\[CLL\\]) received Schedule 2: \\> 12 mg/m\\^2 3 times weekly for Week -1 followed by same dosing frequency as schedule 1 for Weeks 1-4; Schedule 3: \\>=30 mg/m\\^2 PO twice weekly \\[1 day between doses\\]; Schedule 4: \\>=23 mg/m\\^2 PO twice weekly (0 days between doses) to evaluate consecutive dosing; Schedule 5: \\>=30 mg/m\\^2 PO twice weekly (2 days between doses) to evaluate dosing 2 days apart vs. 1 day apart (Schedule 3); Schedule 7: \\>=45 mg/m\\^2 PO once weekly (6 Days between doses) to evaluate vs. twice weekly (Schedules 3, 4, 5, and 6); Schedule 9: \\>=45 mg/m\\^2 PO twice weekly in combination with 375 mg/m\\^2 dose of rituximab IV once weekly for Weeks 1-4 during different cycles. Each cycle was of 28 days or 10 scheduled selinexor doses.","id":"BG004","title":"Other Hematological Malignancies (ALL, CML and CLL)"},{"description":"Total of all reporting groups","id":"BG005","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.00","value":"57.8"},{"groupId":"BG001","spread":"15.90","value":"58.0"},{"groupId":"BG002","spread":"8.76","value":"62.1"},{"groupId":"BG003","spread":"15.33","value":"65.6"},{"groupId":"BG004","spread":"15.23","value":"60.9"},{"groupId":"BG005","spread":"13.79","value":"61.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"38"},{"groupId":"BG003","value":"40"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"123"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"55"},{"groupId":"BG004","value":"16"},{"groupId":"BG005","value":"162"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"72"},{"groupId":"BG003","value":"88"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"258"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"18"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"88"},{"groupId":"BG004","value":"23"},{"groupId":"BG005","value":"248"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"22"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"7"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"}]}],"title":"Native Hawaiian or Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}]}],"title":"American Indian or Alaskan Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"5"}]}],"title":"Unknown/Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Safety population consisted of all participants who received at least 1 dose of selinexor."}